Comparative Pharmacology
Head-to-head clinical analysis: AZACTAM versus CAYSTON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZACTAM versus CAYSTON.
AZACTAM vs CAYSTON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aztreonam is a monobactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 in Gram-negative bacteria, leading to cell death. It is active against aerobic Gram-negative bacilli and has no activity against Gram-positive or anaerobic organisms.
Aztreonam is a monobactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is active against Gram-negative aerobic bacteria including Pseudomonas aeruginosa.
1-2 g intravenously or intramuscularly every 6-8 hours; maximum 8 g/day.
75 mg (one vial) inhaled via nebulizer three times daily, each dose approximately 4 hours apart.
None Documented
None Documented
Terminal elimination half-life: 1.7-2.2 hours in normal renal function. Prolonged to 6-9 hours in end-stage renal disease; not appreciably removed by hemodialysis.
Approximately 2.0–2.5 hours in patients with normal renal function. In patients with moderate renal impairment (CrCl 30–49 mL/min), half-life may be prolonged to ~4.5 hours.
Primarily renal (unchanged drug): 60-75% excreted in urine within 8 hours; 10-15% biliary/fecal. Dosage adjustment required in renal impairment.
Primarily renal; >99% of the absorbed dose is excreted unchanged in urine within 24 hours. No significant biliary or fecal elimination.
Category C
Category C
Monobactam Antibiotic
Monobactam Antibiotic